Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?

Buxbaum JN.

Trends Biochem Sci. 2003 Nov;28(11):585-92. Review.

PMID:
14607088
2.

Molecular mechanisms of amyloidosis.

Merlini G, Bellotti V.

N Engl J Med. 2003 Aug 7;349(6):583-96. Review. No abstract available.

PMID:
12904524
3.

D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?

Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW.

Biochemistry. 2003 Jun 10;42(22):6656-63.

PMID:
12779320
4.

Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.

Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE.

J Protein Chem. 2003 Jan;22(1):31-40.

PMID:
12739896
5.

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG.

Science. 2003 Apr 18;300(5618):486-9.

6.

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Hammarström P, Wiseman RL, Powers ET, Kelly JW.

Science. 2003 Jan 31;299(5607):713-6.

7.

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.

Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16427-32. Epub 2002 Sep 25.

8.

Therapeutic strategies for human amyloid diseases.

Sacchettini JC, Kelly JW.

Nat Rev Drug Discov. 2002 Apr;1(4):267-75. Review.

PMID:
12120278
9.

Only amyloidogenic intermediates of transthyretin induce apoptosis.

Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E.

Biochem Biophys Res Commun. 2002 Jun 7;294(2):309-14.

PMID:
12051711
10.

Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.

Cardoso I, Goldsbury CS, Müller SA, Olivieri V, Wirtz S, Damas AM, Aebi U, Saraiva MJ.

J Mol Biol. 2002 Apr 12;317(5):683-95.

PMID:
11955017
11.

Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.

Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ.

Am J Pathol. 2001 Dec;159(6):1993-2000.

13.
14.

An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.

Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW.

Biochemistry. 2001 Sep 25;40(38):11442-52.

PMID:
11560492
15.

Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.

Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM.

J Biol Chem. 2001 Jul 20;276(29):27207-13. Epub 2001 Apr 16.

16.
17.

The genetics of the amyloidoses.

Buxbaum JN, Tagoe CE.

Annu Rev Med. 2000;51:543-69. Review.

PMID:
10774481
18.

Rational design of potent human transthyretin amyloid disease inhibitors.

Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC.

Nat Struct Biol. 2000 Apr;7(4):312-21. Erratum in: Nat Struct Biol 2000 May;7(5):431.

PMID:
10742177
19.
20.

Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.

Oza VB, Petrassi HM, Purkey HE, Kelly JW.

Bioorg Med Chem Lett. 1999 Jan 4;9(1):1-6.

PMID:
9990446
Items per page

Supplemental Content

Write to the Help Desk